Implicit Bioscience Limited
http://www.implicitbioscience.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Implicit Bioscience Limited
Incyte To Seek Another Monjuvi Approval In Crowded CD19-Targeting Market
Incyte reported positive topline Phase III results for Monjuvi in relapsed or refractory follicular lymphoma and plans to file for US FDA approval by the end of 2024.
Merck Steps Into CD19 Bispecific Antibody Ring With Curon Deal
The drug maker is spending up to $1.3bn to acquire rights to CN201, a CD19xCD3-directed bispecific antibody that it plans to develop for B-cell malignancies and autoimmune diseases.
Recalls Round-Up: Class 1s For BioMérieux, Fresenius, Draeger, More
A spate of recalls released in recent days follow problems with antibiotic test kits, dialysis tubing, an anesthesia system and infusion pumps. About 4,000 complaints have been reported tied to the recalls.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Implicit Bioscience, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice